CN Patent

CN112724052B — 一种gpr101蛋白受体抑制剂及其制备和应用

Assigned to Nanjing Aimeifei Biomedical Technology Co ltd · Expires 2021-09-07 · 5y expired

What this patent protects

本发明提供了一种GPR101蛋白受体抑制剂及其制备和应用，具体地，本发明提供了一种如下式I所示的化合物，或其药学上可接受的盐。所述的化合物具有优异的GPR101蛋白抑制活性。

USPTO Abstract

本发明提供了一种GPR101蛋白受体抑制剂及其制备和应用，具体地，本发明提供了一种如下式I所示的化合物，或其药学上可接受的盐。所述的化合物具有优异的GPR101蛋白抑制活性。

Drugs covered by this patent

Patent Metadata

Patent number
CN112724052B
Jurisdiction
CN
Classification
—
Expires
2021-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Aimeifei Biomedical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.